Pink Eye (Conjunctivitis)



Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo


Condition:   Bacterial Conjunctivitis
Interventions:   Drug: SHP640;   Drug: PVP-I 0.6%;   Drug: Placebo
Sponsor:   Shire
Recruiting - verified April 2017


Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Placebo


Condition:   Adenoviral Conjunctivitis
Interventions:   Drug: SHP640;   Drug: Placebo
Sponsor:   Shire
Recruiting - verified May 2017


Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Povidone-iodine (PVP-I) and Placebo


Condition:   Adenoviral Conjunctivitis
Interventions:   Drug: SHP640;   Drug: PVP-I 0.6%;   Drug: Placebo
Sponsor:   Shire
Recruiting - verified May 2017


A Study of ADX-102 in Subjects With Allergic Conjunctivitis


Condition:   Conjunctivitis, Allergic
Interventions:   Drug: ADX-102 Ophthalmic Drops (0.5%);   Drug: ADX-102 Ophthalmic Drops (0.1%);   Drug: Vehicle of ADX-102 Ophthalmic Drops
Sponsors:   Aldeyra Therapeutics, Inc.;   ORA, Inc.
Active, not recruiting - verified March 2017


Efficacy and Safety of Iota-Carrageenan Eye Drops (NCX-4240)


Condition:   Adenoviral Conjunctivitis
Interventions:   Drug: Iota-Carrageenan;   Drug: Carmellose
Sponsors:   NicOx;   Iris Pharma;   Theradis pharma
Withdrawn - verified May 2017


Study Evaluating the Efficacy and Safety of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis Using a Modified Conjunctival Allergen Challenge Model (CAC®)


Condition:   Chronic Allergic Conjunctivitis
Interventions:   Drug: OTX-DP (Dexamethasone);   Other: Placebo - PV
Sponsors:   Ocular Therapeutix, Inc.;   ORA, Inc.
Completed - verified December 2016


Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis


Condition:   Allergic Conjunctivitis
Interventions:   Biological: ST266;   Drug: Saline (0.9% NaCl)
Sponsor:   Noveome Biotherapeutics, formerly Stemnion
Active, not recruiting - verified January 2017


Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin)


Condition:   Bacterial Conjunctivitis
Interventions:   Drug: PRO-157;   Drug: Vigamox;   Drug: Zymar®;   Drug: Lagricel Ofteno®
Sponsor:   Laboratorios Sophia S.A de C.V.
Completed - verified May 2017


Efficacy and Safety of Grass-SPIRE Registration Study


Conditions:   Rhinitis;   Conjunctivitis
Interventions:   Drug: Grass-SPIRE;   Drug: Placebo
Sponsor:   Circassia Limited
Withdrawn - verified June 2016


Safety and Efficacy of Lastacaft® for the Prevention of Itching Associated With Allergic Conjunctivitis in Korea


Condition:   Conjunctivitis, Allergic
Intervention:   Drug: Alcaftadine Ophthalmic Solution 0.25%
Sponsor:   Allergan
Recruiting - verified November 2016


Reducing Adenoviral Patient Infected Days


Conditions:   Conjunctivitis;   Adenoviral Conjunctivitis
Interventions:   Drug: Betadine 5%;   Drug: Artificial Tears
Sponsors:   Washington University School of Medicine;   University of Alabama at Birmingham;   Illinois College of Optometry;   University of Illinois at Chicago;   Northeastern State University;   Ohio State University;   Massachusetts Eye and Ear Infirmary;   Brooke Army Medical Center;   University of California, Berkeley
Recruiting - verified May 2017


Study Evaluating Efficacy and Safety of OTX-DP for Treatment of Chronic Allergic Conjunctivitis


Condition:   Allergic Conjunctivitis
Interventions:   Drug: OTX-DP treatment;   Device: Placebo Plug with no drug
Sponsors:   Ocular Therapeutix, Inc.;   ORA, Inc.
Completed - verified December 2016


Safety and Efficacy of Vancomycin Ophthalmic Ointment in Patients With Moderate to Severe Bacterial Conjunctivitis


Condition:   Bacterial Conjunctivitis
Interventions:   Drug: Vancomycin 1.1%;   Drug: Placebo
Sponsor:   Kurobe LLC
Recruiting - verified December 2016


Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese Subjects


Condition:   Allergic Conjunctivitis
Interventions:   Drug: Olopatadine Hydrochloride Ophthalmic Solution 0.2%;   Drug: Olopatadine Hydrochloride Ophthalmic Solution 0.1%;   Drug: Olopatadine 0.2% Vehicle
Sponsor:   Alcon Research
Completed - verified October 2016


ADenoVirus Initiative Study in Epidemiology in Spain


Condition:   Viral Conjunctivitis
Intervention:  
Sponsor:   NicOx
Completed - verified January 2017


ADenoVirus Initiative Study in Epidemiology in Italy


Condition:   Viral Conjunctivitis
Intervention:  
Sponsor:   NicOx
Completed - verified February 2017


Phase 2/3 Study Evaluating Efficacy and Safety of OTX-DP for Treatment of Chronic Allergic Conjunctivitis


Condition:   Allergic Conjunctivitis
Interventions:   Drug: OTX-DP treatment;   Device: Placebo Plug with no drug
Sponsors:   Ocular Therapeutix, Inc.;   ORA, Inc.
Completed - verified December 2016


ADenoVirus Initiative Study in Epidemiology in Germany


Condition:   Viral Conjunctivitis
Intervention:  
Sponsor:   NicOx
Completed - verified January 2017


Hydrocortisone Ophthalmic Ointment 0.5% for Treatment of Allergic Conjunctivitis


Condition:   Allergic Conjunctivitis
Interventions:   Drug: hydrocortisone ophthalmic ointment 0.5%;   Drug: placebo
Sponsors:   Koffler Vision Group;   Fera Development, LLC
Terminated - verified March 2017


Efficacy/Safety of Human Plasminogen Eye Drop in Ligneous Conjunctivitis Patients


Condition:   Ligneous Conjunctivitis
Intervention:   Biological: Human Plasminogen
Sponsor:   Kedrion S.p.A.
Active, not recruiting - verified July 2016


Patient Perception Study for AL-4943A


Condition:   Allergic Conjunctivitis
Intervention:   Drug: AL-4943A
Sponsor:   Alcon Research
Completed - verified October 2011


Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis


Condition:   Allergic Conjunctivitis
Interventions:   Drug: Lifitegrast;   Other: Placebo
Sponsor:   Shire
Completed - verified January 2017


Mast-Cell Stabilizing Effects of Olopatadine


Condition:   Allergic Conjunctivitis
Intervention:   Drug: Olopatadine (generic name)
Sponsor:   Alcon Research
Completed - verified January 2010


AL-15469A for the Treatment of Bacterial Conjunctivitis


Condition:   Bacterial Conjunctivitis
Interventions:   Drug: Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%;   Drug: Moxifloxacin hydrochloride ophthalmic solution 0.5% as base
Sponsor:   Alcon Research
Completed - verified March 2012


Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis


Condition:   Allergic Conjunctivitis
Intervention:   Drug: olopatadine 0.2%
Sponsor:   Alcon Research
Completed - verified June 2008

Refine Your Search Advanced Search